During the past decade, James R Berenson MD Inc. conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 9 clinical trials were completed, i.e. on average, 52.9% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 2 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "James R Berenson MD Inc." #1 sponsor was "Oncotherapeutics" with 16 trials, followed by "Amgen" with 2 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored, "Celgene" with 2 trials sponsored and "Avalo Therapeutics, Inc." with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "James R Berenson MD Inc." #1 collaborator was "Amgen" with 3 trials as a collaborator, "Celgene Corporation" with 3 trials as a collaborator, "Millennium Pharmaceuticals, Inc." with 2 trials as a collaborator, "Takeda" with 2 trials as a collaborator and "AbbVie" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "James R Berenson MD Inc." are "Multiple Myeloma" (27 trials), "Fatigue" (1 trials), "Immunocompromised" (1 trials), "Multiple Myeloma and Plasma Cell Neoplasm" (1 trials) and "Newly Diagnosed Multiple Myeloma" (1 trials). Many other conditions were trialed in "James R Berenson MD Inc." in a lesser frequency.

Most popular intervention types in "James R Berenson MD Inc." are "Drug" (28 trials), "Biological" (1 trials), "Device" (1 trials), "Dietary Supplement" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Dexamethasone" (10 trials), "Lenalidomide" (7 trials), "Pomalidomide" (6 trials), "Carfilzomib" (3 trials) and "Elotuzumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "James R Berenson MD Inc." are 32 trials for "All" genders.

Currently, there are NaN active trials in "James R Berenson MD Inc.". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in James R Berenson MD Inc., undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in James R Berenson MD Inc., 16 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".